CA2492022A1 - Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds - Google Patents

Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds Download PDF

Info

Publication number
CA2492022A1
CA2492022A1 CA002492022A CA2492022A CA2492022A1 CA 2492022 A1 CA2492022 A1 CA 2492022A1 CA 002492022 A CA002492022 A CA 002492022A CA 2492022 A CA2492022 A CA 2492022A CA 2492022 A1 CA2492022 A1 CA 2492022A1
Authority
CA
Canada
Prior art keywords
pyrrolo
trimethyl
6alkyl
pyridazine
ethoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002492022A
Other languages
English (en)
French (fr)
Inventor
Naomi Burke Anker
Jeannie M. Arruda
Brian Thomas Campbell
Benito Munoz
Petpiboon Prasit
Brian A. Stearns
Tao Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2492022A1 publication Critical patent/CA2492022A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/503—Pyridazines; Hydrogenated pyridazines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002492022A 2002-07-11 2003-07-08 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds Abandoned CA2492022A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39473402P 2002-07-11 2002-07-11
US60/394,734 2002-07-11
PCT/US2003/021493 WO2004006836A2 (en) 2002-07-11 2003-07-08 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds

Publications (1)

Publication Number Publication Date
CA2492022A1 true CA2492022A1 (en) 2004-01-22

Family

ID=30115760

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002492022A Abandoned CA2492022A1 (en) 2002-07-11 2003-07-08 Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds

Country Status (6)

Country Link
US (1) US7465730B2 (https=)
EP (1) EP1539168A2 (https=)
JP (1) JP2005536507A (https=)
AU (1) AU2003248907B2 (https=)
CA (1) CA2492022A1 (https=)
WO (1) WO2004006836A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY28538A1 (es) 2003-09-26 2005-04-29 Vertex Pharma Derivados de fenil-piperazina como moduladores de receptores muscarínicos
GB0405200D0 (en) * 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
KR20080064956A (ko) 2005-09-27 2008-07-10 미리어드 제네틱스, 인크. 치료학적 화합물로서의 피롤 유도체
CN101003537A (zh) * 2006-01-17 2007-07-25 上海恒瑞医药有限公司 吡咯并哒嗪类衍生物及其制备方法和用途
TW200914457A (en) 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
BRPI0818193B8 (pt) 2007-09-28 2021-05-25 Daiichi Sankyo Co Ltd composto, composição farmacêutica, e, uso de um composto
CN101970427A (zh) 2008-02-29 2011-02-09 Vm生物医药公司 治疗疼痛症状及其它失调的方法
EP2313102A2 (en) * 2008-07-03 2011-04-27 Biota Scientific Management Bycyclic nucleosides and nucleotides as therapeutic agents
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
JP5557292B2 (ja) 2009-03-26 2014-07-23 第一三共株式会社 二環性γ−アミノ酸誘導体の製造方法
HUE035366T2 (en) 2011-06-08 2018-05-02 Daiichi Sankyo Co Ltd A method for the preparation of a bicyclic compound by Claisen rearrangement
ES2659162T3 (es) 2011-06-08 2018-03-14 Daiichi Sankyo Company, Limited Procedimiento de producción de compuesto bicíclico a través de una sal de iminio
KR101944575B1 (ko) 2011-12-15 2019-04-17 다이이찌 산쿄 가부시키가이샤 부제 촉매를 사용하는 2고리형 화합물의 광학 분할 방법
EP2837689B1 (en) 2012-04-10 2017-02-15 Daiichi Sankyo Company, Limited Optical resolution method for bicyclic compound using enzyme
WO2014069626A1 (ja) * 2012-11-01 2014-05-08 協和発酵キリン株式会社 ピリミドジアゼピノン化合物の製造方法
EP2928891B1 (en) 2012-12-04 2019-02-20 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
TWI635071B (zh) 2013-07-08 2018-09-11 第一三共股份有限公司 光學活性二環γ－胺基酸衍生物及其製造方法
WO2018100041A1 (en) * 2016-11-30 2018-06-07 Laboratorios Del Dr. Esteve, S.A. Meta substituted phenylpyrazolo- and phenylpyrrolo- pyridazine derivatives having multimodal activity against pain
EP3548489A1 (en) * 2016-11-30 2019-10-09 Esteve Pharmaceuticals, S.A. Ortho substituted phenylpyrazolo- and phenylpyrrolo-pyridazine derivatives having multimodal activity against pain
US20200062767A1 (en) * 2017-05-30 2020-02-27 Esteve Pharmaceuticals, S.A. Substituted pyrrolidinyl and piperidinyl pyrazolopyridazine derivatives having multimodal activity against pain
GB202106872D0 (en) * 2021-05-13 2021-06-30 Addex Pharmaceuticals Sa Novel compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622948A (en) * 1994-12-01 1997-04-22 Syntex (U.S.A.) Inc. Pyrrole pyridazine and pyridazinone anti-inflammatory agents
GB9726701D0 (en) * 1997-12-18 1998-02-18 Merck Sharp & Dohme Therapeutic use

Also Published As

Publication number Publication date
AU2003248907A1 (en) 2004-02-02
AU2003248907B2 (en) 2007-04-26
JP2005536507A (ja) 2005-12-02
US20060154929A1 (en) 2006-07-13
WO2004006836A3 (en) 2004-04-15
WO2004006836A2 (en) 2004-01-22
EP1539168A2 (en) 2005-06-15
US7465730B2 (en) 2008-12-16

Similar Documents

Publication Publication Date Title
CA2492022A1 (en) Treatment of neuropathic pain with 6h-pyrrolo[3,4-d]pyridazine compounds
EP2282995B1 (en) Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
TWI542590B (zh) １，２-雙取代雜環化合物
Jönsson et al. Synthesis and biological evaluation of new 1, 2-Dihydro-4-hydroxy-2-oxo-3-quinolinecarboxamides for treatment of autoimmune disorders: structure− Activity relationship
EP2155201B1 (en) Quinoxaline derivatives as inhibitors of the tyrosine kinase activity of janus kinases
JP6599852B2 (ja) ブロモドメイン阻害剤としての新規の置換された二環式化合物
JP5508485B2 (ja) 脂質キナーゼ阻害剤としてのイミダゾキノリン
JP4073961B2 (ja) 含窒素複素環化合物
CN100376580C (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并嘧啶
PL196471B1 (pl) Podstawione 3-cyjanochinoliny, sposoby ich otrzymywania, kompozycja farmaceutyczna oraz zastosowanie tych związków w leczeniu
JP2007509150A (ja) 神経障害性疼痛の治療において有用なトリアゾロ−ピリダジン化合物および、この誘導体
KR20140010012A (ko) 글루코세레브로시다제 활성제로서 치환된 피라졸로피리미딘
MX2015001545A (es) Derivados de (aza-)isoquinolinona.
RS53831B1 (sr) Pirazolohinolin derivati kao inhibitori dnk-pk
EP1966212B1 (de) Diazepinone
US20070238734A1 (en) Jnk inhibitors
CN101460223A (zh) 用作诱导型一氧化氮合成酶抑制剂的喹诺酮类
CA2545786A1 (en) Pyridin-4-ylamine compounds useful in the treatment of neuropathic pain
EP3755334A1 (en) Treatment of liver diseases
JP2008526817A (ja) 新規のピロロジヒドロイソキノリン
CN119119035B (zh) 一种ripk1激酶靶点抑制剂及其制备方法与应用
HK40010367A (en) Bicyclic bromodomain inhibitors
MX2008007866A (es) Diazepinonas
JPH01221315A (ja) 中枢神経抑制剤
JPWO1994004504A1 (ja) アポトーシス調整剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued